Helix BioMedix, Inc.

HXBM

US4232875074

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:31:09 2024-02-07 am EST			5-day change	1st Jan Change
23.27 ^USD	-.--%		-.--%	-.--%

2022	Thai, Vietnam rice price hike plan 'impossible', Thai export body says	RE
2019	Helix Biomedix Raises USD 5.62 Million in Debt Funding	CI

Helix BioMedix, Inc. announced that it has received $5.62512 million in funding

July 29, 2019

On July 30, 2019, Helix BioMedix, Inc. (OTCPK:HXBM) closed the transaction. The transaction included participation from a single investor

Latest news about Helix BioMedix, Inc.

Thai, Vietnam rice price hike plan 'impossible', Thai export body says	22-05-30	RE
Helix Biomedix Raises USD 5.62 Million in Debt Funding	19-07-31	CI
Helix BioMedix, Inc. announced that it has received $5.62512 million in funding	19-07-29	CI
Helix BioMedix, Inc. announced that it expects to receive $5.62512 million in funding	19-07-14	CI
Helix BioMedix, Inc. Announces Executive Changes	17-07-10	CI
Helix Biomedix Inc. announced that it has received $1 million in funding	14-12-02	CI
Helix Biomedix Inc. announced that it expects to receive $4.5 million in funding.	14-11-17	CI
Helix Biomedix Inc. announced that it expects to receive $4.5 million in funding.	13-04-18	CI
Helix Biomedix Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012	12-11-09	CI
Helix Biomedix Inc. Reports Unaudited Earnings Results for the Second Quarter and Half Year Ended June 30, 2012; Launches New Apothederm(TM) Acne Clarifying Treatment	12-08-03	CI
Helix Biomedix Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2012	12-05-11	CI
Helix Biomedix Inc. Announces Unaudited Earnings Results for the Year Ended December 31, 2011	12-03-28	CI

Helix BioMedix, Inc. is a peptide discovery and development biopharmaceutical company, which is focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. The Companyâs lead drug development candidate, HB4208, is a deoxyribonucleic damage response enzyme for topical treatment of the rare genetic disorder (orphan disease) Xeroderma Pigmentosum (XP). Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. It is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. It is transforming the treatment of skin conditions by addressing unmet needs in elegant, life-enhancing topical formulations. Its research and development consist of a proprietary library of bioactive peptides based on the bodyâs innate immunity.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HELIX BIOMEDIX, INC.	-.--%	5.23M
IQVIA HOLDINGS INC.	-1.42%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.97%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.82%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.68B
MEDPACE HOLDINGS, INC.	+21.36%	11.6B
UNITED THERAPEUTICS CORPORATION	+8.20%	11.15B

Other Biotechnology & Medical Research